Article Text

Download PDFPDF
Challenge to levetiracetam’s de facto position as generic first-line antiseizure medication

Statistics from Altmetric.com

Footnotes

  • Contributors All three authors were involved in the concept, drafting and final approval of this manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests AN has received a speaking honoria from UCB Pharma and a consultancy fee from SAGE Pharmaceuticals Ltd. MW reports grants from Vitaflo, personal fees from UCB Pharma, personal fees from Eisai, personal fees from GSK, personal fees from Pfizer, personal fees from Special Products, personal fees from Sage pharmaceuticals, personal fees from GW Pharmaceuticals, personal fees from Marinus Pharmaceuticals, outside the submitted work. In addition, Dr Walker has a patent composition for the use in the treatment of epilepsy. WO2018189113A1 licensed, a patent combination comprising decanoic acid for the treatment of epilepsy. WO2019002435A1 pending, a patent therapeutic use of compounds. EP2642990B1 issued, a patent combined use of a vector encoding a modified receptor and its exogenous agonist in the treatment of seizures. US10525103B2 issued, and a patent expression vectors comprising engineered genes. WO2018229254A1 pending. SR has no competing interests.

  • Provenance and peer review Commissioned, externally peer reviewed by Tony Marson, Liverpool, UK.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Other content recommended for you